Abiopharma

🔍 Stedham Adam H (Director)

Company: VerifyMe, Inc. (VRME)

Report Date: 2026-06-19

Detailed Transactions and Holdings:

• Acquired 68,028 shares of Common Stock, par value $0.001 per share (Direct)
  Date: 2026-06-19 | Code: M | equity_swap_involved: 0 | shares_owned_after: 491,397.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 21,897 shares of Common Stock, par value $0.001 per share at $0.6 per share (Direct)
  Date: 2026-06-19 | Code: F | equity_swap_involved: 0 | shares_owned_after: 469,500.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 68,028 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-19 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Holds 550,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-19 | Code: H | shares_owned_after: 550,000.00 | Footnotes: F3, F4, F4
• Holds 152,174 shares of 8% Convertible Promissory Note due 2026 at $1.15 per share (Derivative)
  Date: 2026-06-19 | Code: H | Expires: 2026-08-25 | Exercise: 2023-08-25

Footnotes:

• F1: These restricted stock units, which convert into common stock on a one-for-one basis ("RSUs"), vested on 6/19/2026.
• F2: Includes 28,592 vested RSUs that become payable, on a one-for-one basis, in shares of common stock of VerifyMe, Inc. upon separation of the Reporting Person's service as a director. Also adjusted to increase the amount beneficially owned by 2,359 shares that were inadvertently left off of the Reporting Person's prior Form 4 reports.
• F3: Shares withheld to cover tax withholding obligations on the vesting of RSUs.
• F4: These RSUs will vest upon the earlier of the effective time of the merger, as disclosed and described in VerifyMe, Inc.'s Form S-4 registration statement filed with the SEC, or September 30, 2026.